169 related articles for article (PubMed ID: 17178767)
1. Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes.
Endo T; Ban M; Hirata K; Yamamoto A; Hara Y; Momose Y
Drug Metab Dispos; 2007 Mar; 35(3):476-83. PubMed ID: 17178767
[TBL] [Abstract][Full Text] [Related]
2. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
Spracklin DK; Thummel KE; Kharasch ED
Drug Metab Dispos; 1996 Sep; 24(9):976-83. PubMed ID: 8886607
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.
Zhang W; Kilicarslan T; Tyndale RF; Sellers EM
Drug Metab Dispos; 2001 Jun; 29(6):897-902. PubMed ID: 11353760
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
Draper AJ; Madan A; Parkinson A
Arch Biochem Biophys; 1997 May; 341(1):47-61. PubMed ID: 9143352
[TBL] [Abstract][Full Text] [Related]
5. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.
Komatsu T; Yamazaki H; Shimada N; Nakajima M; Yokoi T
Drug Metab Dispos; 2000 Dec; 28(12):1457-63. PubMed ID: 11095583
[TBL] [Abstract][Full Text] [Related]
6. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
[TBL] [Abstract][Full Text] [Related]
7. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitrosonornicotine alpha-hydroxylation by human liver microsomes.
Patten CJ; Smith TJ; Friesen MJ; Tynes RE; Yang CS; Murphy SE
Carcinogenesis; 1997 Aug; 18(8):1623-30. PubMed ID: 9276639
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
J Pharmacol Exp Ther; 1996 Apr; 277(1):321-32. PubMed ID: 8613937
[TBL] [Abstract][Full Text] [Related]
9. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.
Taguchi K; Konishi T; Nishikawa H; Kitamura S
Xenobiotica; 1999 Sep; 29(9):899-907. PubMed ID: 10548450
[TBL] [Abstract][Full Text] [Related]
10. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes.
Nakashima A; Kawashita H; Masuda N; Saxer C; Niina M; Nagae Y; Iwasaki K
Xenobiotica; 2005 Jun; 35(6):589-602. PubMed ID: 16192110
[TBL] [Abstract][Full Text] [Related]
11. Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes.
Li Y; Li NY; Sellers EM
Eur J Drug Metab Pharmacokinet; 1997; 22(4):295-304. PubMed ID: 9512924
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine.
Endo T; Nakajima M; Fukami T; Hara Y; Hasunuma T; Yokoi T; Momose Y
Pharmacogenet Genomics; 2008 Sep; 18(9):761-72. PubMed ID: 18698229
[TBL] [Abstract][Full Text] [Related]
13. Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.
Wójcikowski J; Pichard-Garcia L; Maurel P; Daniel WA
Br J Pharmacol; 2003 Apr; 138(8):1465-74. PubMed ID: 12721102
[TBL] [Abstract][Full Text] [Related]
14. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes.
Nakajima M; Yamamoto T; Nunoya K; Yokoi T; Nagashima K; Inoue K; Funae Y; Shimada N; Kamataki T; Kuroiwa Y
J Pharmacol Exp Ther; 1996 May; 277(2):1010-5. PubMed ID: 8627511
[TBL] [Abstract][Full Text] [Related]
15. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene.
Taavitsainen P; Juvonen R; Pelkonen O
Drug Metab Dispos; 2001 Mar; 29(3):217-22. PubMed ID: 11181487
[TBL] [Abstract][Full Text] [Related]
16. An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver.
Sai Y; Yang TJ; Krausz KW; Gonzalez FJ; Gelboin HV
Pharmacogenetics; 1999 Apr; 9(2):229-37. PubMed ID: 10376770
[TBL] [Abstract][Full Text] [Related]
17. Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans.
Kimura M; Yamazaki H; Fujieda M; Kiyotani K; Honda G; Saruwatari J; Nakagawa K; Ishizaki T; Kamataki T
Drug Metab Dispos; 2005 Sep; 33(9):1361-6. PubMed ID: 15980104
[TBL] [Abstract][Full Text] [Related]
18. Identification of the human and rat P450 enzymes responsible for the sulfoxidation of S-methyl N,N-diethylthiolcarbamate (DETC-ME). The terminal step in the bioactivation of disulfiram.
Madan A; Parkinson A; Faiman MD
Drug Metab Dispos; 1995 Oct; 23(10):1153-62. PubMed ID: 8654205
[TBL] [Abstract][Full Text] [Related]
19. Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: evidence for major roles by cytochromes P450 2A6 and 2E1.
Duescher RJ; Elfarra AA
Arch Biochem Biophys; 1994 Jun; 311(2):342-9. PubMed ID: 8203896
[TBL] [Abstract][Full Text] [Related]
20. Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes.
Patten CJ; Smith TJ; Murphy SE; Wang MH; Lee J; Tynes RE; Koch P; Yang CS
Arch Biochem Biophys; 1996 Sep; 333(1):127-38. PubMed ID: 8806763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]